Stuart R. Lessin, M.D. is an investigative dermatologist with a research and clinical interest in cutaneous oncology. He has investigated the etiologic role of oncogenic viruses in cutaneous T-cell lymphoma (CTCL) and the molecular mechanisms underlying oncogene and tumor suppressor gene expression in development and tumor progression of CTCL. He has developed techniques for the molecular diagnosis of lymphoproliferative skin diseases based on T-cell receptor (TCR) gene expression.
Dr. Lessin is Professor Emeritus and former Director of Dermatology at the Fox Chase Cancer Center (FCCC) in Philadelphia, Pennsylvania, the nation’s first cancer hospital. While at FCCC, he oversaw clinical care and research programs in melanoma, non-melanoma skin cancer, cutaneous lymphoma, and skin wellness. Dr. Lessin’s clinical trial investigations have focused on the development and testing of topical and skin-directed therapies for skin cancer treatment and prevention.
Dr. Lessin is a co-founder of the Cutaneous Lymphoma Foundation and has served on its Board of Directors since its inception in 1998. He currently serves as President and is an ex-officio member of all Foundation committees including Advocacy, Board Governance, Development, Finance, Medical Affairs, and Programs and Services
Dr. Lessin and his family live in Philadelphia, PA.